Genmab

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has returned or not responded to treatment. About 483 adults who cannot have a stem cell transplant will be randomly as…

This Phase 2 trial tests a new drug called acasunlimab, given alone or with pembrolizumab, in adults with advanced melanoma that worsened after standard treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants receive active treatment…

This study tests an experimental antibody called epcoritamab, given alone or with other drugs, in people with chronic lymphocytic leukemia (CLL) or Richter's syndrome that has come back or not responded to treatment. About 195 adults will receive the drug under the skin or by mou…

This study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal is …

This study tests a new antibody drug, acasunlimab, in people with advanced solid tumors that have not responded to standard treatments. The first part checks safety and finds the best dose, while the second part tests how well it works alone or with other cancer drugs. About 429 …

This study tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then te…

This phase 3 trial tests whether a new drug combination (acasunlimab plus pembrolizumab) works better than standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. About 191 participan…

This early-stage study tests a new drug called GEN1042, alone or with other cancer treatments, in Japanese adults with solid tumors. The main goal is to check safety and find the right dose. About 42 participants will take part.

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 adults in China who cannot have a stem cell transplant will …

This trial tests a new drug called acasunlimab (GEN1046), either alone or with another cancer drug (pembrolizumab), in people with advanced non-small cell lung cancer that came back or didn't respond to standard treatments. About 125 adults will receive the drugs intravenously ev…

This study tests a new combination of drugs (epcoritamab plus lenalidomide) against a standard chemotherapy regimen for adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 379 participants will be randomly assigned to one of thre…

This study tests a new drug called epcoritamab (GEN3013) in people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is an antibody that helps the immune system attack cancer cells. The trial aims to find the best dose, check for side effects, a…

This study tests a drug called epcoritamab, given alone or with lenalidomide, in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy due to age or health issues. About 111 participants will receive active treatment, and researchers will measu…

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …